Gary Rauch
About Gary Rauch
Vice President of Finance at Q/C Technologies, Inc. (Nasdaq: QCLS; formerly TNF Pharmaceuticals) with finance leadership continuity from the Company’s predecessor Akers Biosciences; prior role listed as Treasurer/VP Finance at Akers Biosciences (LinkedIn) . Education, age, and tenure start date are not publicly disclosed. As a non-NEO, executive-specific performance metrics (TSR, revenue/EBITDA growth) tied to his tenure are not disclosed; company-level filings note ongoing going-concern risk and heavy reliance on equity financing .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Akers Biosciences, Inc. | Treasurer / VP, Finance | Not disclosed | Finance leadership continuity into current entity following corporate transformations |
External Roles
No public director or external board roles disclosed.
Fixed Compensation
Not disclosed in proxy/filings for this non-NEO executive.
Performance Compensation
RSU awards approved by the Board on Oct 3, 2025; structure is event-/time-based rather than metric-weighted. Additional plan notes below.
| Metric/Instrument | Weighting | Target | Actual/Payout | Vesting |
|---|---|---|---|---|
| RSUs – Initial Grant to Gary Rauch (1,080 units) | n/a | n/a | Granted and fully vested on Grant Date (Oct 3, 2025) | Immediate vesting |
| RSUs – Additional Grant to Gary Rauch (11,420 units) | n/a | Stockholder approval of Plan share increase | To be issued and fully vest upon stockholder approval | Full vesting contingent on Plan amendment approval |
| 2021 Equity Incentive Plan Clawback | n/a | Restatement trigger | Company may recoup awards per clawback policy, if any | Per Plan governance |
Notes:
- Plan-level anti-hedging/anti-pledging: Company states it does not maintain a policy restricting hedging/pledging by employees/directors (red flag for alignment) .
- Insider Trading Policy exists and governs trading procedures .
Insider Transactions (Form 4 / Awards)
| Date | Type | Units | Price | Security | Notes |
|---|---|---|---|---|---|
| 2025-10-03 (reported 2025-10-06) | Acquisition (Non-Open Market) – RSUs | 1,080 | $0.00 | QCLS Common (RSUs) | Initial RSUs, vested on grant date |
| 2025-10-03 (reported 2025-10-06) | Award filing reference | — | — | SEC Form 4 | Insider profile reference |
Equity Ownership & Alignment
| Category | Amount | Detail |
|---|---|---|
| RSUs – Vested | 1,080 | Vested on Oct 3, 2025 |
| RSUs – Unvested (Pending issuance) | 11,420 | Fully vest contingent on shareholder approval to increase Plan shares |
| Shares owned (common) | Not disclosed | No director/NEO table listing for this executive |
| Ownership guidelines | Not disclosed | No company-wide executive ownership guideline disclosed |
| Hedging/Pledging | No formal prohibition | Company does not maintain an anti-hedging/anti-pledging policy |
Employment Terms
- Title: Vice President of Finance .
- Employment agreement, severance, change-of-control terms: Not disclosed for this non-NEO executive.
- Company-level clawback language embedded in 2021 Plan (policy “if any”) .
Risk Indicators & Red Flags
- No anti-hedging/anti-pledging policy: Weakens alignment; increases risk of hedging/pledging practices by insiders .
- Immediate vesting of RSUs (1,080) and fully vesting “Additional RSUs” upon shareholder approval raises near-term liquidity/selling pressure risk once shares are issued .
- Company going-concern language and reliance on dilutive financings (preferred stock/warrants) heighten governance/compensation inflation risks and potential equity overhang .
- Clawback only “if any” policy: Ambiguity on actual enforcement mechanisms .
Investment Implications
- Near-term supply risk: Contingent RSUs (11,420) will fully vest upon plan approval, potentially increasing insider sellable inventory and adding to float/overhang in a thin-cap, dilution-prone issuer .
- Alignment gap: Lack of anti-hedging/pledging policy and time/event-based RSUs (vs. robust performance PSU structures) weaken pay-for-performance rigor .
- Governance vigilance: With going-concern risk and recurring equity financings, monitor insider filings, vesting events, and board/shareholder actions on plan amendments and clawback implementation .
Additional Context:
- Corporate rename/ticker change: TNF Pharmaceuticals, Inc. changed name to Q/C Technologies, Inc.; trading symbol changed from TNFA to QCLS effective Sept 25, 2025 .
- Gary Rauch’s prior finance role at Akers Biosciences indicates continuity of financial leadership through corporate transitions .
Sources:
Role/RSU grants: ; Name/ticker change: ; Anti-hedging policy & Insider Trading policy: ; Clawback language: ; Company going-concern risk: ; Insider award references: ; Prior role (LinkedIn):